{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:20:15Z","timestamp":1761488415869,"version":"build-2065373602"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Elderly patients with acute myeloid leukemia (AML) are generally unable to withstand the rigors of intensive induction chemotherapy and its attendant complications. Gemtuzumab ozogamicin (GO) is an immunoconjugate that had demonstrated activity in recurrent AML.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The objective of the current study was to determine the prognostic factors for achievement of complete remission (CR) in newly diagnosed elderly AML patients treated with GO as initial induction therapy. A retrospective study was performed of efficacy and toxicity associated with GO therapy, and factors potentially predictive of response were assessed in 49 previously untreated AML patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>CR was achieved in 14% of all treated patients. Among the patients with an intermediate\u2010risk karyotype, the CR rate was 30%, compared with none with an unfavorable karyotype. The median duration of overall survival was 3.7 months (95% confidence interval [95% CI], 1.4\u20106.9 months), and the median recurrence\u2010free survival in patients who achieved CR was 11.8 months (95% CI, 5.0\u2010ind months).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>These data suggest that GO should be considered as a first\u2010line treatment option in older patients with AML with intermediate\u2010risk cytogenetics who cannot tolerate high\u2010dose induction chemotherapy. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25078","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T11:52:01Z","timestamp":1269949921000},"page":"3001-3005","source":"Crossref","is-referenced-by-count":11,"title":["Gemtuzumab ozogamicin as first\u2010line treatment in patients aged 70 years or older with acute myeloid leukemia"],"prefix":"10.1002","volume":"116","author":[{"given":"Wassim","family":"McHayleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Foon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Redner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Raptis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounzer","family":"Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"The Minh","family":"Luong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Schlesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boyiadzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_2","DOI":"10.3322\/canjclin.52.6.363"},{"doi-asserted-by":"publisher","key":"e_1_2_6_3_2","DOI":"10.1182\/blood-2005-09-3724"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1002\/cncr.21723"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_2","DOI":"10.1038\/sj.onc.1210364"},{"key":"e_1_2_6_6_2","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross PF","year":"2001","journal-title":"Clin Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_2_6_7_2","DOI":"10.1002\/cncr.21326"},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_2","DOI":"10.1200\/JCO.2001.19.13.3244"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_2","DOI":"10.1517\/14712598.8.4.527"},{"doi-asserted-by":"publisher","key":"e_1_2_6_10_2","DOI":"10.1016\/j.ctrv.2007.09.001"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_2","DOI":"10.1038\/sj.leu.2403901"},{"key":"e_1_2_6_12_2","first-page":"950","article-title":"Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML\u201015) of the EORTC and GIMEMA leukemia groups","volume":"89","author":"Amadori S","year":"2004","journal-title":"Haematologica."},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_2","DOI":"10.1182\/blood.V99.12.4343"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_2","DOI":"10.1016\/j.leukres.2004.04.011"},{"doi-asserted-by":"publisher","key":"e_1_2_6_15_2","DOI":"10.1080\/1042819021000016078"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_2","DOI":"10.1200\/JCO.2003.04.036"},{"doi-asserted-by":"publisher","key":"e_1_2_6_17_2","DOI":"10.1182\/asheducation-2007.1.429"},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_2","DOI":"10.1002\/cncr.22496"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1182\/blood.V112.11.2957.2957","article-title":"Preliminary results of a Phase II study of low dose decitabine as a single agent in older patients (age \u226560) with previously untreated acute myeloid leukemia (AML)","volume":"112","author":"Blum W","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V112.11.560.560","article-title":"Preliminary results of a multicenter phase II trial of 5\u2010day decitabine as front\u2010line therapy for elderly patients with acute myeloid leukemia (AML)","volume":"112","author":"Cashen AF","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood.V112.11.4041.4041","article-title":"Azacitidine in the treatment of elderly patients with acute myelogenous leukemia","volume":"112","author":"Labban G","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.V112.11.2985.2985","article-title":"Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high\u2010risk myelodysplastic syndrome","volume":"112","author":"Borthakur G","year":"2008","journal-title":"Blood."},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_2","DOI":"10.1080\/10428190802451254"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25078","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:36:52Z","timestamp":1760287012000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,6,15]]}},"alternative-id":["10.1002\/cncr.25078"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25078","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}